Optonol
Miniature Surgical Implants for Glaucoma Patients
Startup Acquired Health Tech & Life Sciences Est. 1996 Acquired
🌐 WebsiteLinkedIn
Total Raised
$30M
Acquired
Last Round
$20M
2 rounds
Investors
5
5 public
Team
3
1-10 employees
Confidence
85/100
News
1
articles
Patents
1
About
Optonol's flagship product, Ex-Press, is a miniature surgical implant used to lower intra-ocular pressure in patients with glaucoma. Optonol was founded as a spin-off of Jerusalem-based stent developer Medinol Ltd. Optonol was acquired by Alcon in December 2009. A year later, Alcon was acquired by Novartis.
Classification
Sector
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Core Technology
Materials & SubstancesImplants
Target Customer
Healthcare & Life SciencesHealthcareProviders
Business Model
B2B
Tags
imagingmedical-devicesglaucoma
Funding & Events
Mar 2000
Seed $10M
Avi Fischer, Eli Yones, Naomi Blumenthal
Dec 2009
Exit $150M
Apr 2006
A Round $20M
Israel HealthCare Ventures, Pitango VC
News (1)
Dec 14, 2009 · www.globes.co.il
growth-positive
Alcon buys Israeli glaucoma treatment co Optonol
Acquisition
Details
Product Stage
Released
Employees
1-10
Exact Count
10
District
Jerusalem District
Founded
1996
Registrar
512051236
Crunchbase
optonol
Locations
Neve Ilan, Israel
Links
Website
optonol.com
LinkedIn
Profile
Admin
Last Update
Feb 17, 2022
Verified by
Jenny Sotnik-Talisman
Missing
not claimed, video or image, markets
Team (3)
Yaron Ira
Co-founder (No longer with the company)
Founder
Benad Goldwasser
Co-founder (No longer with the company)
Founder
Jonathan Koltin
General Manager
Internal
Created by
Natalia Golczar (ngolczar@gmail.com)
Created
2017-09-27T00:00:00.000Z
Last editor
Orli Wollner (orlushka@gmail.com)
Status
Acquired by Alcon on Dec, 2009
Finder · Optonol · 2026